120 related articles for article (PubMed ID: 25139631)
21. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
22. Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory.
Bonora E; Cataudella S; Marchesini G; Miccoli R; Vaccaro O; Fadini GP; Martini N; Rossi E;
Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2661-2668. PubMed ID: 34218990
[TBL] [Abstract][Full Text] [Related]
23. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
Strongman H; D'Oca K; Langerman H; Das R
Diabetes Obes Metab; 2015 Jun; 17(6):573-580. PubMed ID: 25735201
[TBL] [Abstract][Full Text] [Related]
24. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
Schrijnders D; Houweling ST; Landman GW
Diabetes Care; 2015 Jun; 38(6):e94. PubMed ID: 25998308
[No Abstract] [Full Text] [Related]
25. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Overbeek JA; Heintjes EM; Prieto-Alhambra D; Blin P; Lassalle R; Hall GC; Lapi F; Bianchini E; Hammar N; Bezemer ID; Herings RMC
Clin Ther; 2017 Apr; 39(4):759-770. PubMed ID: 28342563
[TBL] [Abstract][Full Text] [Related]
26. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
Genuth S
Diabetes Care; 2015 Jun; 38(6):e95. PubMed ID: 25998309
[No Abstract] [Full Text] [Related]
27. Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Wood SJ; Magliano DJ; Bell JS; Shaw JE; Keen CS; Ilomäki J
Diabet Med; 2020 Aug; 37(8):1367-1373. PubMed ID: 31557346
[TBL] [Abstract][Full Text] [Related]
28. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.
Campbell DJT; Campbell DB; Ogundeji Y; Au F; Beall R; Ronksley PE; Quinn AE; Manns BJ; Hemmelgarn BR; Tonelli M; Spackman E
Diabet Med; 2021 Sep; 38(9):e14622. PubMed ID: 34133781
[TBL] [Abstract][Full Text] [Related]
29. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
[TBL] [Abstract][Full Text] [Related]
30. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
31. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
32. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients.
Dailey G; Kim MS; Lian JF
J Int Med Res; 2002; 30(1):71-9. PubMed ID: 11921502
[TBL] [Abstract][Full Text] [Related]
33. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
[TBL] [Abstract][Full Text] [Related]
34. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
Enders D; Kollhorst B; Engel S; Linder R; Verheyen F; Pigeot I
J Diabetes Complications; 2016; 30(7):1339-46. PubMed ID: 27245402
[TBL] [Abstract][Full Text] [Related]
35. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Konrad K; Datz N; Engelsberger I; Grulich-Henn J; Hoertenhuber T; Knauth B; Meissner T; Wiegand S; Woelfle J; Holl RW;
Pediatr Diabetes; 2015 Nov; 16(7):529-37. PubMed ID: 25131985
[TBL] [Abstract][Full Text] [Related]
36. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
37. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
40. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; Blanes-Castañer V; López-Menchero R; Gisbert-Sellés C; Sánchez-Jodar C; Alvarez-Avellán L
Nefrologia; 2012 May; 32(3):367-73. PubMed ID: 22592422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
